Clinical Trial Update: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating Modakafusp Alfa in combination with Daratumumab for adults with relapsed or refractory multiple myeloma has been terminated; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Modakafusp Alfa (modakafusp alfa)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-06